Conversely, a cohort study by St-Pierre et al. involving 36 IBD patients who initiated semaglutide or tirzepatide for weight loss found no significant changes in CRP levels in the 25 patients that had repeated CRP measurements (median baseline CRP was 3 mg/L (IQR: 3–6.5 mg/L), which remained unchanged at the end of follow-up [31]. The gene discussed is CRP; the disease is inflammatory bowel disease.